BioSpace News Archive

The Canadian Dermatology Association is proud to announce the recipients of the CDA Shade Structure Grant Program, which helps public schools, daycares, city parks and non-profit organizations create sun-safe environments in their communities.

Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in an upcoming virtual investor conference. Jigar Raythatha, CEO, will present at the Jefferies Virtual Healthcare Conference at 2:30 PM EDT on June 2. A live audio webcast of Mr. Raythatha’s presentation and archives

First-Of-Its Kind Coalition Will Convene Healthcare Leaders To Address The Extraordinary Challenges Faced By Minorities With A Rare Disease

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2 at 4:00 p.m. ET. The presentation will be webcast live and may be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations . About Sangamo Therapeutics Sangam

GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Chief Executive Officer Rachel King will provide a company overview at the upcoming Jefferies Virtual Healthcare Conference. The presentation will be available on the company’s website at the “Investors” tab for 30 days, beginning Thursday, June 4 from 1:00 – 1:25 p.m. EDT. To access the live webcast and subsequent archived recordings for the presentation, please

Investigators at MedStar Washington Hospital Center and Nagourney Cancer Institute report the results of a study that examined the impact of prior FOLFOX chemotherapy exposure on Oxaliplatin resistance

Quest Diagnostics Incorporated (NYSE: DGX), the world’s leading provider of diagnostic information services, announced that it is scheduled to speak at the Jefferies Virtual Healthcare Conference.

Menlo Therapeutics Inc. (Nasdaq: MNLO) (“Menlo” or the “Company”), a specialty pharmaceutical company focused on developing and commercializing proprietary therapies to address unmet needs in dermatology, today announced that the U.S. Food and Drug Administration (FDA) has approved ZILXI

BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey, Interim Chief Executive Officer, and Terry Coelho, Chief Financial Officer, will present at two upcoming investor conferences in June

The U.S. Food and Drug Administration took steps to further support the development of COVID-19 tests for at-home self-collection by including a voluntary EUA template for at-home sample collection kits to its website.